Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

Figure 5

Synergistic induction of apoptosis by anti-MCSP:TRAIL and rimcazole A. A375M cells were treated with increasing concentrations of anti-MCSP:TRAIL in the presence or absence of rimcazole for 16 h and apoptosis was assessed by ∆ψ. B A375M cells were treated with rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/ml) or both for 16 h, apoptosis was assessed by ∆ψ and the cooperativity index (CI) was calculated as indicated in the materials and methods section. C A375M cells were treated with rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/mL) or both in the presence or absence of pentacozine (200 nM) for 16 h and apoptosis was assessed by ∆ψ. D Hepatocytes were treated with, rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/ml) or both for 16 h and apoptosis was assessed by ∆ψ. KillerFasL (100 ng/ml)was used as a positive control for hepatocyte toxicity.

Back to article page

Molecular Cancer

ISSN: 1476-4598